Risk of volume depletion events with concomitant use of sodium glucose co‐transporter 2 inhibitors and loop diuretics: A self‐controlled case series study. Issue 10 (1st July 2022)

• Record Type: Journal Article
• Authors: Lewellyan, Colleen M.; Spoutz, Patrick; Schaefer, Monica; Patterson, Mark E.
• Is Part Of: Pharmacoepidemiology and drug safety. Volume 31:Issue 10(2022)
• Page Start: 1102
• Page End: 1109
• Publication Date: 2022-07-01
• Subjects: loop diuretic -- sodium‐glucose co‐transporter 2 inhibitor -- volume depletion; Pharmacoepidemiology -- Periodicals; Chemotherapy -- Periodicals; Epidemiology -- Periodicals; 615.705
• DOI: 10.1002/pds.5496
• Languages: English
• ISSNs: 1053-8569

Abstract

Abstract: Background: Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are used to prevent cardiovascular complications in type 2 diabetes mellitus (T2DM) and newly indicated to treat heart failure (HF). Loop diuretics are commonly prescribed to manage volume overload in HF and may increase the risk of volume depletion in real‐world practice. This study evaluated the risk of volume depletion following concomitant use of SGLT2is and loop diuretics in veterans. Methods: Veterans with T2DM were included if they received concomitant loop diuretics and SGLT2is and experienced at least one volume depletion event between December 2012 and December 2019, utilizing a self‐controlled case series design. Concomitant prescribing periods were divided into focal windows of 1 to 14 days, 14 to 28 days, and greater than 28 days. Incidence rate ratios (IRR) were estimated using multivariable Poisson regressions adjusted for age and renal function. Results: 3352 patients experienced at least one volume depletion event and were concomitantly prescribed SGLT2is and loop diuretics at least once. The risk of volume depletion increased in the treatment versus control windows during the 1 to 14‐day window (IRR = 1.82, 95% CI 1.63–2.02) the 15‐to‐28‐day window (IRR = 1.46, 95% CI 1.28–1.67), and the greater than 28‐day window (IRR = 1.22, 95% CI 1.21–1.34). Conclusions: Concomitant prescribing of SGLT2is and loop diuretics is associated with an increased risk of volume depletion, an effect that attenuates with longer therapy durations. Prescribers need to closely monitor fluid status in patients receiving concomitant therapy, especially those with advancing age or with eGFR below 60.